25.90
price up icon1.97%   0.50
 
loading
前日終値:
$25.40
開ける:
$25.71
24時間の取引高:
13.76M
Relative Volume:
1.32
時価総額:
$10.71B
収益:
$3.14B
当期純損益:
$-3.36B
株価収益率:
-2.9668
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
-2.89%
1か月 パフォーマンス:
-7.47%
6か月 パフォーマンス:
-34.25%
1年 パフォーマンス:
-80.73%
1日の値動き範囲:
Value
$25.42
$26.02
1週間の範囲:
Value
$25.06
$26.75
52週間の値動き範囲:
Value
$23.15
$138.07

Moderna Inc Stock (MRNA) Company Profile

Name
名前
Moderna Inc
Name
セクター
Healthcare (1174)
Name
電話
(617) 714-6500
Name
住所
325 BINNEY STREET, CAMBRIDGE
Name
職員
5,800
Name
Twitter
@moderna_tx
Name
次回の収益日
2025-02-14
Name
最新のSEC提出書
Name
MRNA's Discussions on Twitter

MRNA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MRNA
Moderna Inc
25.90 10.71B 3.14B -3.36B -4.03B -8.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Moderna Inc Stock (MRNA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 開始されました Citigroup Neutral
2025-02-18 ダウングレード Barclays Overweight → Equal Weight
2025-01-29 ダウングレード Goldman Buy → Neutral
2024-12-18 ダウングレード Argus Buy → Hold
2024-12-10 再開されました BofA Securities Underperform
2024-11-19 開始されました Berenberg Hold
2024-11-18 アップグレード HSBC Securities Hold → Buy
2024-11-15 開始されました Wolfe Research Underperform
2024-10-17 開始されました Bernstein Mkt Perform
2024-09-13 ダウングレード JP Morgan Neutral → Underweight
2024-09-13 ダウングレード Jefferies Buy → Hold
2024-09-13 ダウングレード Oppenheimer Outperform → Perform
2024-08-28 アップグレード HSBC Securities Reduce → Hold
2024-08-07 アップグレード Deutsche Bank Sell → Hold
2024-08-05 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-02-26 ダウングレード HSBC Securities Hold → Reduce
2024-01-02 アップグレード Oppenheimer Perform → Outperform
2023-11-29 開始されました Canaccord Genuity Hold
2023-11-03 アップグレード HSBC Securities Reduce → Hold
2023-11-02 ダウングレード Deutsche Bank Hold → Sell
2023-08-04 ダウングレード TD Cowen Outperform → Market Perform
2023-08-03 ダウングレード Deutsche Bank Buy → Hold
2023-07-24 開始されました William Blair Mkt Perform
2023-07-14 開始されました HSBC Securities Reduce
2023-06-26 アップグレード UBS Neutral → Buy
2023-04-26 開始されました Guggenheim Neutral
2023-03-13 アップグレード TD Cowen Market Perform → Outperform
2023-03-02 開始されました RBC Capital Mkts Outperform
2023-02-24 ダウングレード SVB Securities Market Perform → Underperform
2022-12-19 アップグレード Jefferies Hold → Buy
2022-12-14 ダウングレード Chardan Capital Markets Buy → Neutral
2022-10-21 アップグレード SVB Leerink Underperform → Mkt Perform
2022-09-08 アップグレード Deutsche Bank Hold → Buy
2022-02-01 アップグレード Redburn Sell → Neutral
2022-01-26 アップグレード Deutsche Bank Sell → Hold
2022-01-21 アップグレード BofA Securities Underperform → Neutral
2022-01-21 開始されました UBS Neutral
2021-12-07 開始されました Cowen Market Perform
2021-11-09 開始されました Wolfe Research Outperform
2021-10-22 開始されました Deutsche Bank Sell
2021-10-15 アップグレード Piper Sandler Neutral → Overweight
2021-08-06 ダウングレード Oppenheimer Outperform → Perform
2021-08-06 ダウングレード Piper Sandler Overweight → Neutral
2021-07-15 繰り返されました Jefferies Hold
2021-02-01 ダウングレード BofA Securities Neutral → Underperform
2020-12-16 ダウングレード Jefferies Buy → Hold
2020-12-16 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-12-09 ダウングレード Needham Buy → Hold
2020-11-23 開始されました Wells Fargo Equal Weight
2020-11-17 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-09-08 ダウングレード SVB Leerink Mkt Perform → Underperform
2020-07-23 開始されました SVB Leerink Mkt Perform
2020-07-20 ダウングレード JP Morgan Overweight → Neutral
2020-07-13 開始されました Jefferies Buy
2020-06-30 開始されました Argus Buy
2020-06-08 開始されました Barclays Overweight
2020-04-30 開始されました BMO Capital Markets Outperform
2020-03-05 ダウングレード BofA/Merrill Buy → Neutral
2019-12-03 再開されました BofA/Merrill Buy
2019-10-25 開始されました ROTH Capital Buy
2019-04-05 開始されました Chardan Capital Markets Buy
すべてを表示

Moderna Inc (MRNA) 最新ニュース

pulisher
Jun 18, 2025

BDF Gestion Invests $783,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Moderna’s SWOT analysis: mRNA pioneer’s stock faces pivotal moment - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Trump administration cancels Moderna contract to fight bird flu and other viruses - Arizona Daily Star

Jun 18, 2025
pulisher
Jun 18, 2025

Moderna (MRNA) Sees Bullish Trading Activity with Increased Options Volume | MRNA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Zika Virus Therapeutics Market Size & Share | Industry Growth [2032] - SkyQuest Technology

Jun 18, 2025
pulisher
Jun 17, 2025

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Moderna (MRNA) Sees Bearish Sentiment Among Option Traders | MRNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

SG Americas Securities LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Rakuten Securities Inc. Has $742,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Moderna (NASDAQ:MRNA) Stock Price Down 3.8%Here's What Happened - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Moderna, Inc.Special Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Tobam - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Union Bancaire Privee UBP SA Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Moderna | History, Innovation, Challenges, & Facts - Britannica

Jun 15, 2025
pulisher
Jun 14, 2025

FDA approves Moderna’s new COVID-19 vaccine - Santa Clarita Valley Signal

Jun 14, 2025
pulisher
Jun 14, 2025

FDA approves expanded use of Moderna’s RSV shot - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo

Jun 14, 2025
pulisher
Jun 14, 2025

GAMMA Investing LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Moderna’s SWOT analysis: mrna stock faces challenges amid vaccine shifts - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Here's Why Moderna (MRNA) Fell More Than Broader Market - sharewise

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

FDA expands approval of Moderna’s RSV vaccine to some adults under age 60 - weisradio.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA expands approval of Moderna's RSV vaccine to some adults under age 60 - WBAL News Radio

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains - The Hill

Jun 13, 2025
pulisher
Jun 13, 2025

IBM and Moderna tout use cases for AI in total rewards - HR Brew

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna falls on doubts over new CDC panel's backing of RSV vaccine - Reuters

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna (MRNA) Faces Challenges Despite RSV Vaccine Approval - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna wins FDA OK to widen use of RSV vaccine - BioPharma Dive

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna Stock Falls on CDC Panel Concerns Over RSV VaccineNews and Statistics - IndexBox

Jun 13, 2025
pulisher
Jun 13, 2025

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 - The Boston Globe

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna under pressure despite RSV vaccine approval into wider age group - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults - The Pharma Letter

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna (MRNA) Faces Intensified Short Selling Amid Challenges - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - TradingView

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology - BioSpace

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna's RSV shot gets US nod for use in younger adults - pharmaphorum

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna (MRNA) Gains FDA Approval for Expanded RSV Vaccine Use - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

FDA expands Moderna's RSV vaccine approval to at-risk adults (MRNA:NASDAQ) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Knoxville News Sentinel

Jun 13, 2025
pulisher
Jun 13, 2025

Moderna Gets FDA Approval for mRESVIA in Adults Aged 18-59 at Increased Risk for RSV Disease - marketscreener.com

Jun 13, 2025
pulisher
Jun 12, 2025

Moderna (MRNA) Receives FDA Nod for RSV Vaccine Extended Use | M - GuruFocus

Jun 12, 2025

Moderna Inc (MRNA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
大文字化:     |  ボリューム (24 時間):